Science
Avilex Pharma is developing best in class neuroprotectants
The treatment
AVLX-144

AVLX-144 - a best in class neuroprotectant
Avilex Pharma is developing a pipeline of novel inhibitors of PDZ domain proteins to target unmet medical needs. Our lead candidate – AVLX-144 – is a dimeric peptide-like drug candidate for the treatment of acute ischemic stroke, which targets the intracellular scaffolding protein, postsynaptic density protein 95 (PSD-95). AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor, and a clinical lead candidate for the treatment of acute conditions such as subarachnoid hemorrhage (SAH) and acute ischemic stroke (AIS).
PSD-95 bridges the glutamate receptor subtype, the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS) via its two PDZ domains. This is specifically exploited by AVLX-144, which binds to both these PDZ domains in PSD-95 simultaneously. The specific design of AVLX-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability and enhanced in vivo neuroprotective properties.
Key
References
